Neu­rol­o­gists pass on Aduhelm again. Most agree with CMS de­ci­sion to lim­it cov­er­age, study finds

A ma­jor­i­ty of neu­rol­o­gists agree with Medicare on the need for more da­ta on Bio­gen and Ei­sai’s Alzheimer’s dis­ease med Aduhelm, de­spite FDA ap­proval.

More than half (52%) of neu­rol­o­gists agree with the Cen­ters for Medicare and Med­ic­aid Ser­vices (CMS) pro­posed de­ci­sion in Jan­u­ary to lim­it cov­er­age to pa­tients in clin­i­cal tri­als, Spher­ix Glob­al In­sights’ lat­est study found. On­ly 15% dis­agreed with the de­ci­sion, while the rest were neu­tral.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.